PROCF (Sofgen Pharma) Short-Term Debt: $265.3 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PROCF Sofgen Pharma SA PROCF
24 GF Score
Price $0.00
View Full Analysis

What is Sofgen Pharma Short-Term Debt?

Sofgen Pharma PROCF 24 Short-Term Debt is $265.3 Mil as of Dec. 2024. GuruFocus rates PROCF with a GF Score™ of 24/100.

Sofgen Pharma's Short-Term Debt for the quarter that ended in Dec. 2024 was $265.3 Mil.

Sofgen Pharma's quarterly Short-Term Debt increased from Sep. 2023 ($69.2 Mil) to Dec. 2023 ($268.4 Mil) but then declined from Dec. 2023 ($268.4 Mil) to Dec. 2024 ($265.3 Mil).

Sofgen Pharma's annual Short-Term Debt increased from Dec. 2022 ($257.9 Mil) to Dec. 2023 ($268.4 Mil) but then declined from Dec. 2023 ($268.4 Mil) to Dec. 2024 ($265.3 Mil).

Sofgen Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sofgen Pharma Short-Term Debt Related Terms

Sofgen Pharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Sofgen Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sofgen Pharma Short-Term Debt Chart

Sofgen Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial 114.78 224.32 257.90 268.39 265.31

Sofgen Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 135.11 118.68 69.24 268.39 265.31
PROCF
24GF Score
Sofgen Pharma SA PROCF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $265.3 Mil mean?
Sofgen Pharma (PROCF) has a Short-Term Debt of $265.3 Mil as of Dec. 2024.
Is Sofgen Pharma's Short-Term Debt too high?
Sofgen Pharma's current Short-Term Debt is $265.3 Mil. Overall, Sofgen Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sofgen Pharma's Short-Term Debt compare to BKUH and ORGO?
Sofgen Pharma's Short-Term Debt of $265.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Sofgen Pharma's current Short-Term Debt is $265.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sofgen Pharma stock overvalued right now?
Sofgen Pharma (PROCF) has a current Short-Term Debt of $265.3 Mil. The current Short-Term Debt is $265.3 Mil. Sofgen Pharma's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Sofgen Pharma (PROCF), the current Short-Term Debt is $265.3 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sofgen Pharma Business Description

Address 9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is an integrated healthcare and pharmaceutical company that develops and manufactures pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The company's segment includes NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. It generates maximum revenue from the NextGel segment. It has geographic presence in Bolivia, Brazil, Colombia, Costa Rica, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Panama, Peru, and the United States.
24GF Score

Get the complete analysis for PROCF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price